iSign Solutions (ISGN) 10-Q 16 May 22 2022 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2022	May 16, 2022
Document Information Line Items
Entity Registrant Name	iSign Solutions Inc.
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		6,332,736
Amendment Flag	false
Entity Central Index Key	0000727634
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Mar. 31, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q1
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	000-19301
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	94-2790442
Entity Address, Address Line One	2033 Gateway Place
Entity Address, Address Line Two	Suite 659
Entity Address, City or Town	San Jose
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	95110
City Area Code	(650)
Local Phone Number	802-7888
Entity Interactive Data Current	Yes

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 56	$ 40
Accounts receivable, net of allowance of $3 at March 31, 2022 and $0 at December 31, 2021.	94	124
Prepaid expenses and other current assets	15	22
Total current assets	165	186
Property and equipment, net	7	5
Other assets	5	5
Total assets	177	196
Current liabilities:
Accounts payable	396	378
Short-term debt – related party	1,402	1,002
Short-term debt other	1,542	2,022
Accrued compensation	88	69
Deferred compensation	219	219
Other accrued liabilities	1,556	1,488
Deferred revenue	339	196
Total current liabilities	5,542	5,374
Long-term debt - other	45	45
Other long-term liabilities	645	608
Total liabilities	6,232	6,027
Commitments and contingencies
Stockholders’ deficit:
Common stock, $0.01 par value; 2,000,000 shares authorized; 6,332 shares issued and outstanding at March 31, 2022 and 6,322 at December 31, 2021, respectively	63	63
Treasury shares, 5 at March 31, 2022 and December 31, 2021, respectively	(325)	(325)
Additional paid in capital	130,127	130,120
Accumulated deficit	(135,920)	(135,689)
Total stockholders’ deficit	(6,055)	(5,831)
Total liabilities and stockholders’ deficit	$ 177	$ 196

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parentheticals) - USD ($) shares in Thousands, $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Accounts receivable, net of allowance (in Dollars)	$ 3	$ 0
Common stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	2,000,000	2,000,000
Common stock, shares issued	6,322	6,322
Common stock, shares outstanding	6,322	6,322
Treasury shares	5	5

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenue:
Product	$ 80	$ 82
Maintenance	175	177
Total revenue	255	259
Cost of sales:
Product	2	10
Maintenance	18	20
Research and development	161	144
Sales and marketing	54	49
General and administrative	160	147
Total operating costs and expenses	395	370
Loss from operations	(140)	(111)
Other income (expense) net		1
Interest expense:
Related party	(39)	(24)
Other	(52)	(55)
Loss before income tax expense	(231)	(189)
Income tax expense		(1)
Net loss	$ (231)	$ (190)
Basic and diluted net loss per common share (in Dollars per share)	$ (0.04)	$ (0.03)
Weighted average common shares outstanding, basic and diluted (in Shares)	6,329	5,762

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders’ Deficit (Unaudited) - USD ($) $ in Thousands	Common Stock	Treasury Stock	Additional Paid-in Capital	Accumulated Deficit	Total
Balance at Dec. 31, 2020	$ 58	$ (325)	$ 129,783	$ (135,203)	$ (5,687)
Balance (in Shares) at Dec. 31, 2020	5,762	5
Stock-based compensation			24		24
Net loss				(190)	(190)
Balance at Mar. 31, 2021	$ 58	$ (325)	129,807	(135,393)	(5,853)
Balance (in Shares) at Mar. 31, 2021	5,762	5
Balance at Dec. 31, 2021	$ 63	$ (325)	130,120	(135,689)	(5,831)
Balance (in Shares) at Dec. 31, 2021	6,322	5
Stock-based compensation			7		7
Cashless exercise of warrants
Cashless exercise of warrants (in Shares)	10
Net loss				(231)	(231)
Balance at Mar. 31, 2022	$ 63	$ (325)	$ 130,127	$ (135,920)	$ (6,055)
Balance (in Shares) at Mar. 31, 2022	6,332	5

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash flows from operating activities:
Net loss	$ (231)	$ (190)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization	1	1
Stock-based compensation	7	24
Changes in operating assets and liabilities:
Accounts receivable, net	30	31
Prepaid expenses and other assets	7	(2)
Accounts payable	18	27
Accrued compensation	19	34
Other accrued and long-term liabilities	105	118
Deferred revenue	143	179
Net cash provided by operating activities	99	222
Cash flows from investing activities:
Acquisition of property and equipment	(3)	(3)
Net cash used in investing activities	(3)	(3)
Cash flows from financing activities:
Proceeds from of short term debts related party		40
Proceeds from the issuance of short-term debt other	50	45
Payment of short term debts related party	(30)	(20)
Payment of short term debts other	(100)	(60)
Net cash provided by (used in) financing activities	(80)	5
Net increase in cash and cash equivalents	16	224
Cash and cash equivalents at beginning of period	40	26
Cash and cash equivalents at end of period	56	250
Supplementary disclosure of cash flow information
Interest paid	$ 28	5
Income taxes paid		1
Accounts receivable advance converted to convertible note		$ 15

Nature of Business and Summary

Nature of Business and Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Nature of Business and Summary of Significant Accounting Policies	1. Nature of Business and Summary of Significant Accounting Policies Nature of Business iSign Solutions Inc. and its subsidiary is a leading supplier of digital transaction management (DTM) software enabling the paperless, secure and cost-effective management and authentication of document-based transactions. iSign’s solutions encompass a wide array of functionality and services, including electronic signatures, simple-to-complex workflow management and various options for biometric authentication. These solutions are available across virtually all enterprise, desktop and mobile environments as a seamlessly integrated platform for both ad-hoc and fully automated transactions. iSign’s platform can be deployed both on premise and as a cloud-based (“SaaS”) service, with the ability to easily transition between deployment models. The Company is headquartered in San Jose, California. The Company’s products include SignatureOne™ Ceremony™ Server, the iSign™ suite of products and services, including iSign™ Enterprise and iSign™ Console™, and Sign-it™ programs. In December 2019, an outbreak of a novel strain of coronavirus (COVID-19) originated in Wuhan, China and has since spread to a number of other countries, including the U.S. On March 11, 2020, the World Health Organization characterized COVID-19 as a pandemic. Since March 11, 2020 states in the U.S., including California, where the Company is headquartered, have begun to open up as the result of the development of vaccines to thwart the spread of the virus. The COVID-19 outbreak has disrupted supply chains and affected production and sales across a wide range of industries. The extent of the impact of COVID-19 on our operational and financial performance will depend on certain developments, including the duration and any further spread of the outbreak, continued impact on our customers, employees and vendors all of which are uncertain and cannot be predicted. At this point, the extent to which COVID-19 may have a continued impact on our financial condition or results of operations is uncertain. Basis of Presentation The financial information contained herein should be read in conjunction with the Company’s consolidated audited financial statements and notes thereto included in its Annual Report on Form 10-K for the year ended December 31, 2021. The accompanying unaudited condensed consolidated financial statements of the Company have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America (“GAAP”) for complete consolidated financial statements. In the opinion of management, the unaudited condensed consolidated financial statements included in this quarterly report reflect all adjustments (consisting only of normal recurring adjustments) that the Company considers necessary for a fair presentation of its financial position at the dates presented and the Company’s results of operations and cash flows for the periods presented. The Company’s interim results are not necessarily indicative of the results to be expected for the entire year. Going Concern The accompanying unaudited condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred significant cumulative losses since its inception and, at March 31, 2022 the Company’s accumulated deficit was $135,920. The Company has primarily met its working capital needs through the sale of debt and equity securities. As of March 31, 2022, the Company’s cash balance was $56. These factors raise substantial doubt about the Company’s ability to continue as a going concern. There can be no assurance that the Company will be successful in securing adequate capital resources to fund planned operations or that any additional funds will be available to the Company when needed, or if available, will be available on favorable terms or in amounts required by the Company. If the Company is unable to obtain adequate capital resources to fund operations, it may be required to delay, scale back or eliminate some or all of its operations, which may have a material adverse effect on the Company’s business, results of operations and ability to operate as a going concern. The unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Accounting Changes and Recent Accounting Pronouncements Accounting Standards Updates issued in 2022 are not currently applicable to the Company, therefore implementation would not be expected to have a material impact on the Company’s financial position, results of operations and cash flows.

Concentrations

Concentrations	3 Months Ended
	Mar. 31, 2022
Risks and Uncertainties [Abstract]
Concentrations	2. Concentrations The following table summarizes accounts receivable and revenue concentrations: Accounts Receivable Total Revenue 2022 2021 2022 2021 Customer #1 91 % 92 % 35 % 25 % Customer #2 - - 25 % 27 % Customer #3 - - 20 % 28 % Total concentration 91 % 92 % 80 % 80 %

Net Loss Per Share

Net Loss Per Share	3 Months Ended
	Mar. 31, 2022
Net Loss Per Share [Abstract]
Net Loss Per Share	3. Net Loss Per Share The Company calculates basic net loss per share based on the weighted average number of shares outstanding, and when applicable, diluted net income per share, which is based on the weighted average number of shares and potential dilutive shares outstanding. The following table lists shares and warrants that were excluded from the calculation of diluted earnings per share as the inclusion of shares from the assumed exercise of such options and warrants would be anti-dilutive: For the Three Months Ended March 31, March 31, Common stock subject to outstanding options 1,322 1,338 Common stock subject to outstanding warrants 450 3,001 Common stock subject to outstanding convertible debt plus accrued interest 7,556 7,025

Debt

Debt	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
Debt	4. Debt Advances: On January 19 and February 9, 2022, the Company repaid $15 and $15, respectively, of accounts receivable advances from related parties along with $2 of accrued advance fees. In addition, on February 2022, the Company repaid $100 of demand notes to an unrelated party along with 20% of accrued fees. Notes payable: In January 2022, the Company received, from unrelated parties, demand notes aggregating $50 in cash. The notes bear interest at the rate of 20% per annum. Principal and interest due shall be paid in full on demand, following ten (10) calendar day prior written notices starting on March 15, 2022. These note may be prepaid in whole or in part at any time without penalty, premium or other consideration by giving at least five (5) business day prior written notice to the Holder. The notes were repaid in full plus $1 of accrued interest in February 2022. During the three months ended March 31, 2022, the Company accrued $91 of interest expense, $67 associated with the outstanding secured and unsecured convertible promissory notes, of which $30 was to related parties and $37 was to other investors. For the three months ended March 31, 2021, the Company accrued $79 of interest expense, $67 associated with its outstanding notes, of which $24 was to related parties and $43 was to other investors.

Stockholders' Deficit

Stockholders' Deficit	3 Months Ended
	Mar. 31, 2022
Stockholders' Equity Note [Abstract]
Stockholders' Deficit	5. Stockholders’ Deficit Stock-based compensation expense is based on the estimated grant date fair value of the portion of stock-based payment awards that are ultimately expected to vest during the period. The grant date fair value of stock-based awards to employees and directors is calculated using the Black-Scholes-Merton valuation model. Forfeitures of stock-based payment awards are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The estimated average forfeiture rate for the three months ended March 31, 2022 and 2021 was approximately 1.73% and 4.78%, respectively, based on historical data. Valuation and Expense Information: The weighted-average fair value of stock-based compensation is based on the Black-Scholes-Merton valuation model. Forfeitures are estimated and it is assumed no dividends will be declared. The estimated fair value of stock-based compensation awards to employees is amortized over the vesting period of the options. No options were granted during the three months ended March 31, 2022 and 2021. There were no stock options exercised during the three months ended March 31, 2022 and 2021, respectively. The following table summarizes the allocation of stock-based compensation expense for the three months ended March 31: 2022 2021 General and administrative $ 5 $ 17 Director 2 7 Total stock-based compensation $ 7 $ 24 A summary of option activity under the Company’s plans for the three months ended March 31, 2022 and 2021 is as follows: 2022 2021 Options Shares Weighted Weighted Aggregate Shares Weighted Weighted Aggregate Outstanding at January 1 1,338 $ 0.84 − $ 800 1,338 $ 0.87 − − Granted − $ − − − $ − − − Canceled 16 $ 28.12 24.57 − − $ − Outstanding at March 31 1,322 $ 0.60 0.50 $ 1,100 1,338 $ 0.87 4.35 − Vested and expected to vest at March 31 1,322 $ 0.84 3.17 $ 1,100 1,320 $ 0.88 3.99 $ − Exercisable at March 31 1,182 $ 0.61 3.14 $ 967 1,018 $ 0.97 3.86 $ − The following table summarizes significant ranges of outstanding and exercisable options as of March 31, 2022: Options Outstanding Options Exercisable Range of Exercise Prices Number Weighted Weighted Number Weighted $0.01 - $0.50 927 0.50 $ 3.39 787 $ 0.50 $0.51 - $1.00 393 0.78 $ 3.36 393 $ 0.78 $1.01 - $25.00 2 15.94 $ 0.33 2 $ 15.94 Total 1,322 0.60 $ 3.38 1,181 $ 0.61 A summary of the status of the Company’s non-vested shares as of March 31, 2022 is as follows: Non-vested Shares Shares Weighted Average Non-vested at January 1, 2022 172 $ 0.50 Vested (32 ) $ 0.57 Non-vested at March 31, 2022 140 $ 0.50 As of March 31, 2022, there was $17 of total unrecognized compensation expense related to non-vested stock-based compensation arrangements granted under the plans. The unrecognized compensation expense is expected to be realized over a weighted average period of one year. Warrants The Company did not issue any warrants during the three months ended March 31, 2022 and 2021. A summary of the warrant activity to purchase shares of Common Stock for the three months ended March 31 is as follows: 2022 2021 Shares Weighted Shares Weighted Outstanding at beginning of period 1,450 $ 1.52 3,001 $ 1.37 Issued − $ − − $ − Exercised (15 ) $ 0.50 − $ − Expired (985 ) $ 0.50 − $ − Outstanding at end of period 450 $ 0.50 3,001 $ 1.37 Exercisable at end of period 450 $ 0.50 3,001 $ 1.37 A summary of the status of the warrants outstanding and exercisable to purchase shares of Common Stock as of March 31, 2022 is as follows: Number of Shares Weighted Average Weighted Average 15 0.84 $ 0.50 10 3.32 $ 0.50 425 1.38 $ 0.50 450 1.41 $ 0.50

Subsequent Event

Subsequent Event	3 Months Ended
	Mar. 31, 2022
Subsequent Events [Abstract]
Subsequent event	6. Subsequent event On April 20, 2022, the Company issued an aggregate of $125 in unsecured convertible notes, $70 to related parties and $55 to other investors. The unsecured notes are convertible by the holder into common stock at any time at a price per share of $1.00. Upon closing a new financing of at least $1,000 in aggregate proceeds, the Company can force conversion at a price equal to the lesser of $1.00 per share or the price per share of the new financing. The notes bear interest at the rate of 10% per annum and are due December 31, 2022. Forward Looking Statements Certain statements contained in this quarterly report on Form 10-Q, including, without limitation, statements containing the words “believes”, “anticipates”, “hopes”, “intends”, “expects”, and other words of similar import, constitute “forward looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors which may cause actual events to differ materially from expectations. Such factors include those set forth in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, including the following: ● Technological, engineering, manufacturing, quality control or other circumstances that could delay the sale or shipment of products; ● Economic, business, market and competitive conditions in the software industry and technological innovations that could affect the Company’s business; ● The Company’s inability to protect its trade secrets or other proprietary rights, operate without infringing upon the proprietary rights of others and prevent others from infringing on the proprietary rights of the Company; and ● General economic and business conditions and the availability of sufficient financing. Except as otherwise required by applicable laws, the Company undertakes no obligation to publicly update or revise any forward-looking statements, as a result of new information, future events or otherwise.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Nature of Business	Nature of Business iSign Solutions Inc. and its subsidiary is a leading supplier of digital transaction management (DTM) software enabling the paperless, secure and cost-effective management and authentication of document-based transactions. iSign’s solutions encompass a wide array of functionality and services, including electronic signatures, simple-to-complex workflow management and various options for biometric authentication. These solutions are available across virtually all enterprise, desktop and mobile environments as a seamlessly integrated platform for both ad-hoc and fully automated transactions. iSign’s platform can be deployed both on premise and as a cloud-based (“SaaS”) service, with the ability to easily transition between deployment models. The Company is headquartered in San Jose, California. The Company’s products include SignatureOne™ Ceremony™ Server, the iSign™ suite of products and services, including iSign™ Enterprise and iSign™ Console™, and Sign-it™ programs. In December 2019, an outbreak of a novel strain of coronavirus (COVID-19) originated in Wuhan, China and has since spread to a number of other countries, including the U.S. On March 11, 2020, the World Health Organization characterized COVID-19 as a pandemic. Since March 11, 2020 states in the U.S., including California, where the Company is headquartered, have begun to open up as the result of the development of vaccines to thwart the spread of the virus. The COVID-19 outbreak has disrupted supply chains and affected production and sales across a wide range of industries. The extent of the impact of COVID-19 on our operational and financial performance will depend on certain developments, including the duration and any further spread of the outbreak, continued impact on our customers, employees and vendors all of which are uncertain and cannot be predicted. At this point, the extent to which COVID-19 may have a continued impact on our financial condition or results of operations is uncertain.
Basis of Presentation	Basis of Presentation The financial information contained herein should be read in conjunction with the Company’s consolidated audited financial statements and notes thereto included in its Annual Report on Form 10-K for the year ended December 31, 2021. The accompanying unaudited condensed consolidated financial statements of the Company have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America (“GAAP”) for complete consolidated financial statements. In the opinion of management, the unaudited condensed consolidated financial statements included in this quarterly report reflect all adjustments (consisting only of normal recurring adjustments) that the Company considers necessary for a fair presentation of its financial position at the dates presented and the Company’s results of operations and cash flows for the periods presented. The Company’s interim results are not necessarily indicative of the results to be expected for the entire year.
Going Concern	Going Concern The accompanying unaudited condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred significant cumulative losses since its inception and, at March 31, 2022 the Company’s accumulated deficit was $135,920. The Company has primarily met its working capital needs through the sale of debt and equity securities. As of March 31, 2022, the Company’s cash balance was $56. These factors raise substantial doubt about the Company’s ability to continue as a going concern. There can be no assurance that the Company will be successful in securing adequate capital resources to fund planned operations or that any additional funds will be available to the Company when needed, or if available, will be available on favorable terms or in amounts required by the Company. If the Company is unable to obtain adequate capital resources to fund operations, it may be required to delay, scale back or eliminate some or all of its operations, which may have a material adverse effect on the Company’s business, results of operations and ability to operate as a going concern. The unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
Accounting Changes and Recent Accounting Pronouncements	Accounting Changes and Recent Accounting Pronouncements Accounting Standards Updates issued in 2022 are not currently applicable to the Company, therefore implementation would not be expected to have a material impact on the Company’s financial position, results of operations and cash flows.

Concentrations (Tables)

Concentrations (Tables)	3 Months Ended
	Mar. 31, 2022
Risks and Uncertainties [Abstract]
Schedule of accounts receivable and revenue concentrations	Accounts Receivable Total Revenue 2022 2021 2022 2021 Customer #1 91 % 92 % 35 % 25 % Customer #2 - - 25 % 27 % Customer #3 - - 20 % 28 % Total concentration 91 % 92 % 80 % 80 %

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2022
Net Loss Per Share [Abstract]
Schedule of options and warrants would be anti-dilutive	For the Three Months Ended March 31, March 31, Common stock subject to outstanding options 1,322 1,338 Common stock subject to outstanding warrants 450 3,001 Common stock subject to outstanding convertible debt plus accrued interest 7,556 7,025

Stockholders' Deficit (Tables)

Stockholders' Deficit (Tables)	3 Months Ended
	Mar. 31, 2022
Stockholders' Equity Note [Abstract]
Schedule of stock-based compensation expense	2022 2021 General and administrative $ 5 $ 17 Director 2 7 Total stock-based compensation $ 7 $ 24
Schedule of option activity under the Company's plans	2022 2021 Options Shares Weighted Weighted Aggregate Shares Weighted Weighted Aggregate Outstanding at January 1 1,338 $ 0.84 − $ 800 1,338 $ 0.87 − − Granted − $ − − − $ − − − Canceled 16 $ 28.12 24.57 − − $ − Outstanding at March 31 1,322 $ 0.60 0.50 $ 1,100 1,338 $ 0.87 4.35 − Vested and expected to vest at March 31 1,322 $ 0.84 3.17 $ 1,100 1,320 $ 0.88 3.99 $ − Exercisable at March 31 1,182 $ 0.61 3.14 $ 967 1,018 $ 0.97 3.86 $ −
Schedule of significant ranges of outstanding and exercisable options	Options Outstanding Options Exercisable Range of Exercise Prices Number Weighted Weighted Number Weighted $0.01 - $0.50 927 0.50 $ 3.39 787 $ 0.50 $0.51 - $1.00 393 0.78 $ 3.36 393 $ 0.78 $1.01 - $25.00 2 15.94 $ 0.33 2 $ 15.94 Total 1,322 0.60 $ 3.38 1,181 $ 0.61
Schedule of the company's non-vested shares	Non-vested Shares Shares Weighted Average Non-vested at January 1, 2022 172 $ 0.50 Vested (32 ) $ 0.57 Non-vested at March 31, 2022 140 $ 0.50
Schedule of warrant activity	2022 2021 Shares Weighted Shares Weighted Outstanding at beginning of period 1,450 $ 1.52 3,001 $ 1.37 Issued − $ − − $ − Exercised (15 ) $ 0.50 − $ − Expired (985 ) $ 0.50 − $ − Outstanding at end of period 450 $ 0.50 3,001 $ 1.37 Exercisable at end of period 450 $ 0.50 3,001 $ 1.37
Schedule of warrants outstanding and exercisable	Number of Shares Weighted Average Weighted Average 15 0.84 $ 0.50 10 3.32 $ 0.50 425 1.38 $ 0.50 450 1.41 $ 0.50

Nature of Business and Summar_2

Nature of Business and Summary of Significant Accounting Policies (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Accumulated deficit	$ (135,920)	$ (135,689)
Cash	$ 56

Concentrations (Details) - Sche

Concentrations (Details) - Schedule of accounts receivable and revenue concentrations - Customer Concentration Risk [Member]	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Accounts Receivable [Member]
Variable Interest Entity [Line Items]
Total concentration	91.00%	92.00%
Accounts Receivable [Member] | Customer #1 [Member]
Variable Interest Entity [Line Items]
Total concentration	91.00%	92.00%
Accounts Receivable [Member] | Customer #2 [Member]
Variable Interest Entity [Line Items]
Total concentration
Accounts Receivable [Member] | Customer #3 [Member]
Variable Interest Entity [Line Items]
Total concentration
Total Revenue [Member]
Variable Interest Entity [Line Items]
Total concentration	80.00%	80.00%
Total Revenue [Member] | Customer #1 [Member]
Variable Interest Entity [Line Items]
Total concentration	35.00%	25.00%
Total Revenue [Member] | Customer #2 [Member]
Variable Interest Entity [Line Items]
Total concentration	25.00%	27.00%
Total Revenue [Member] | Customer #3 [Member]
Variable Interest Entity [Line Items]
Total concentration	20.00%	28.00%

Net Loss Per Share (Details) -

Net Loss Per Share (Details) - Schedule of options and warrants would be anti-dilutive - shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Schedule of options and warrants would be anti-dilutive [Abstract]
Common stock subject to outstanding options	1,322	1,338
Common stock subject to outstanding warrants	450	3,001
Common stock subject to outstanding convertible debt plus accrued interest	7,556	7,025

Debt (Details)

Debt (Details) - USD ($) $ in Thousands	Feb. 09, 2022	Jan. 19, 2022	Feb. 28, 2022	Mar. 31, 2022	Mar. 31, 2021	Jan. 31, 2022
Debt Disclosure [Abstract]
Advance accounts receivable	$ 15	$ 15
Accrued advances unpaid	$ 2
Accounts receivable advances repaid			$ 100
Accrued fees percentage			20.00%
Accounts receivable advances in cash						$ 50
Percentage of bear interest rate						20.00%
Accrued interest expense			$ 1
Interest expense				$ 91	$ 79
Amount of outstanding secured and unsecured convertible promissory notes				67
Amount of related parties				30	24
Amount of other investors				$ 37	43
Amount of outstanding notes					$ 67

Stockholders' Deficit (Details)

Stockholders' Deficit (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Stockholders' Equity Note [Abstract]
Percentage of estimated average forfeiture rate	1.73%	4.78%
Total unrecognized compensation expense (in Dollars)	$ 17
Weighted average period	1 year

Stockholders' Deficit (Detail_2

Stockholders' Deficit (Details) - Schedule of stock-based compensation expense - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Stockholders' Deficit (Details) - Schedule of stock-based compensation expense [Line Items]
Total stock-based compensation	$ 7	$ 24
Director [Member]
Stockholders' Deficit (Details) - Schedule of stock-based compensation expense [Line Items]
Total stock-based compensation	2	7
General and administrative [Member]
Stockholders' Deficit (Details) - Schedule of stock-based compensation expense [Line Items]
Total stock-based compensation	$ 5	$ 17

Stockholders' Deficit (Detail_3

Stockholders' Deficit (Details) - Schedule of option activity under the Company's plans - Option [Member] - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Stockholders' Deficit (Details) - Schedule of option activity under the Company's plans [Line Items]
Shares, Outstanding at beginning	1,338	1,338
Weighted Average Exercise Price per share, outstanding at beginning	$ 0.84	$ 0.87
Weighted Average Remaining Contractual Term (Years), outstanding at beginning
Aggregate Intrinsic Value, outstanding at beginning	$ 800
Shares, Granted
Weighted Average Exercise Price Per Share, Granted
Weighted Average Remaining Contractual Term (Years), Granted
Aggregate Intrinsic Value, Granted
Shares, Canceled	16
Weighted Average Exercise Price Per Share, Canceled	$ 28.12
Weighted Average Remaining Contractual Term (Years), Canceled	24 years 6 months 25 days
Aggregate Intrinsic Value, Canceled
Shares, outstanding at ending	1,322	1,338
Weighted Average Exercise Price per share, outstanding at ending	$ 0.6	$ 0.87
Weighted Average Remaining Contractual Term (Years), outstanding at ending	6 months	4 years 4 months 6 days
Aggregate Intrinsic Value, outstanding at ending	$ 1,100
Shares, Vested and expected to vest	1,322	1,320
Weighted Average Exercise Price per share, Vested and expected to vest	$ 0.84	$ 0.88
Weighted Average Remaining Contractual Term (Years), Vested and expected to vest	3 years 2 months 1 day	3 years 11 months 26 days
Aggregate Intrinsic Value, Vested and expected to vest	$ 1,100
Shares, Exercisable	1,182	1,018
Weighted Average Exercise Price per share, Exercisable	$ 0.61	$ 0.97
Weighted Average Remaining Contractual Term (Years), Exercisable	3 years 1 month 20 days	3 years 10 months 9 days
Aggregate Intrinsic Value, Exercisable	$ 967

Stockholders' Deficit (Detail_4

Stockholders' Deficit (Details) - Schedule of significant ranges of outstanding and exercisable options	3 Months Ended
	Mar. 31, 2022$ / sharesshares
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Number Outstanding | shares	1,322
Options Outstanding, Weighted Average Remaining Contractual Life (in years)	7 months 6 days
Options Outstanding, Weighted Average Exercise Price | $ / shares	$ 3.38
Options Exercisable, Number Outstanding | shares	1,181
Options Exercisable, Weighted Average Exercise Price | $ / shares	$ 0.61
$0.01 – $25.00 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Number Outstanding | shares	927
Options Outstanding, Weighted Average Remaining Contractual Life (in years)	6 months
Options Outstanding, Weighted Average Exercise Price | $ / shares	$ 3.39
Options Exercisable, Number Outstanding | shares	787
Options Exercisable, Weighted Average Exercise Price | $ / shares	$ 0.5
$0.51 - $1.00 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Number Outstanding | shares	393
Options Outstanding, Weighted Average Remaining Contractual Life (in years)	9 months 10 days
Options Outstanding, Weighted Average Exercise Price | $ / shares	$ 3.36
Options Exercisable, Number Outstanding | shares	393
Options Exercisable, Weighted Average Exercise Price | $ / shares	$ 0.78
$1.01 - $25.00 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Number Outstanding | shares	2
Options Outstanding, Weighted Average Remaining Contractual Life (in years)	15 years 11 months 8 days
Options Outstanding, Weighted Average Exercise Price | $ / shares	$ 0.33
Options Exercisable, Number Outstanding | shares	2
Options Exercisable, Weighted Average Exercise Price | $ / shares	$ 15.94

Stockholders' Deficit (Detail_5

Stockholders' Deficit (Details) - Schedule of the company's non-vested shares	3 Months Ended
	Mar. 31, 2022$ / sharesshares
Schedule of the company's non-vested shares [Abstract]
Shares, Non-vested at beginning | shares	172
Weighted Average Grant-Date Fair Value, Shares | $ / shares	$ 0.5
Shares, Vested | shares	(32)
Weighted Average Grant-Date Fair Value, Vested | $ / shares	$ 0.57
Shares, Non-vested at ending | shares	140
Weighted Average Grant-Date Fair Value, Non-vested at ending | $ / shares	$ 0.5

Stockholders' Deficit (Detail_6

Stockholders' Deficit (Details) - Schedule of warrant activity - Warrant [Member] - $ / shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Stockholders' Deficit (Details) - Schedule of warrant activity [Line Items]
Shares Outstanding at beginning of period	1,450	3,001
Weighted Average Exercise Price Per Share, Outstanding at beginning of period	$ 1.52	$ 1.37
Shares, Issued
Weighted Average Exercise Price Per Share, Issued
Shares, Exercised	(15)
Weighted Average Exercise Price Per Share, Exercised	$ 0.5
Shares, Expired	(985)
Weighted Average Exercise Price Per Share, Expired	$ 0.5
Shares, Outstanding at end of period	450	3,001
Weighted Average Exercise Price Per Share, Outstanding at end of period	$ 0.5	$ 1.37
Shares, Exercisable at end of period	450	3,001
Weighted Average Exercise Price Per Share, Exercisable at end of period	$ 0.5	$ 1.37

Stockholders' Deficit (Detail_7

Stockholders' Deficit (Details) - Schedule of warrants outstanding and exercisable	3 Months Ended
	Mar. 31, 2022$ / sharesshares
Stockholders' Deficit (Details) - Schedule of warrants outstanding and exercisable [Line Items]
Number of Shares | shares	450
Weighted Average Remaining Life	1 year 4 months 28 days
Weighted Average Exercise Price per share | $ / shares	$ 0.5
Warrants Group Two [Member]
Stockholders' Deficit (Details) - Schedule of warrants outstanding and exercisable [Line Items]
Number of Shares | shares	15
Weighted Average Remaining Life	10 months 2 days
Weighted Average Exercise Price per share | $ / shares	$ 0.5
Warrants Group Three [Member]
Stockholders' Deficit (Details) - Schedule of warrants outstanding and exercisable [Line Items]
Number of Shares | shares	10
Weighted Average Remaining Life	3 years 3 months 25 days
Weighted Average Exercise Price per share | $ / shares	$ 0.5
Warrants Group Four [Member]
Stockholders' Deficit (Details) - Schedule of warrants outstanding and exercisable [Line Items]
Number of Shares | shares	425
Weighted Average Remaining Life	1 year 4 months 17 days
Weighted Average Exercise Price per share | $ / shares	$ 0.5

Subsequent Event (Details)

Subsequent Event (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended
	Apr. 20, 2022	Dec. 31, 2022
Subsequent Event [Member]
Subsequent Event (Details) [Line Items]
Unsecured convertible notes	$ 125
Related parties amount	70
Other investors amount	$ 55
Common stock price per share (in Dollars per share)	$ 1
Aggregate proceeds	$ 1,000
Conversion price per share (in Dollars per share)	$ 1
Forecast [Member]
Subsequent Event (Details) [Line Items]
Interest rate		10.00%